Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cardiff Oncology (CRDF) reported a narrower third-quarter net loss while its Phase 2 colorectal cancer trial remained ongoing. Net loss was $8.857 million versus $11.258 million a year earlier; loss per share was $0.12 versus $0.17.
Median progression-free survival, or time without disease worsening, was not reached in the 30 mg onvansertib plus FOLFIRI/bevacizumab arm, versus approximately 11 months in the combined standard-of-care arms. Patients remaining in that onvansertib arm had received treatment for at least 21 months. Cardiff expects a Phase 3 start in Q1 2027, subject to additional financing.
Cash, cash equivalents and short-term investments totaled approximately $33.8 million at September 30. Cardiff expects these resources to fund operations through the end of Q3 2027. Nine-month operating cash use increased to approximately $33.9 million from $31.9 million.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointJuly offering raised $10 million gross and approximately $9.1 million net. 17% of market cap
- Moderate pointMedian progression-free survival was not reached in the 30 mg onvansertib/FOLFIRI/bevacizumab arm versus approximately 11 months in combined controls.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 3 preparations target a Q1 2027 start, with vendor relationships and companion diagnostics being finalized.
- Moderate pointGlobal onvansertib rights disputes with Nerviano Medical Sciences were resolved; the exclusive license agreement was amended in September.
- Moderate pointQ3 net loss narrowed to $8.857 million from $11.258 million; loss per share narrowed to $0.12 from $0.17.
- Moderate pointNine-month net loss narrowed to $30.434 million from $38.635 million; loss per share narrowed to $0.43 from $0.58.
8 minor points
- Minor pointRemaining patients in the 30 mg onvansertib/FOLFIRI/bevacizumab arm reached at least 21 months on treatment; longest exceeded 29 months.
- Minor pointFDA orphan drug designations granted for onvansertib in chronic myelomonocytic leukemia in October and small cell lung cancer in November.
- Minor pointQ3 royalty revenue rose to $171,000 from $120,000 a year earlier.
- Minor pointQ3 research and development expense fell to $5.029 million from $8.197 million a year earlier.
- Minor pointQ3 operating loss narrowed to $9.219 million from $11.974 million a year earlier.
- Minor pointNine-month research and development expense fell to $17.709 million from $30.254 million a year earlier.
- Minor pointNine-month operating loss narrowed to $31.684 million from $41.133 million a year earlier.
- Minor pointTotal liabilities fell to $8.316 million at September 30, 2026, from $16.496 million at December 31, 2025.
Negative
- Major pointCommon stock and warrants issued in the July registered direct offering dilute existing holders.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 3 initiation remains subject to securing additional financing.
- Moderate pointNine-month operating cash use increased to approximately $33.9 million from $31.9 million a year earlier.
- Moderate pointNine-month selling, general and administrative expense rose to $14.291 million from $11.229 million a year earlier.
- Minor pointCash and cash equivalents fell to $12.060 million from $17.470 million at December 31, 2025.
5 minor points
- Minor pointShort-term investments fell to $21.730 million from $40.834 million at December 31, 2025.
- Minor pointQ3 selling, general and administrative expense rose to $4.361 million from $3.897 million a year earlier.
- Minor pointNine-month royalty revenue declined to $316,000 from $350,000 a year earlier.
- Minor pointInterest income fell to $363,000 from $716,000 in Q3 and $1.251 million from $2.492 million over nine months.
- Minor pointStockholders’ equity declined to $28.098 million at September 30, 2026, from $45.388 million at December 31, 2025.
News Explained
In July, Cardiff completed a
Details
Market move: CRDF -4.93% in the Nov 12 session. 3Q26 earnings report
On Nov 12, the day this news came out, CRDF closed 4.93% below the previous close. Our momentum scanner recorded 3 alerts for this stock that day.
Data tracked by StockTitan Argus for the Nov 12 session.
Key Figures
- Median PFS, 30 mg onvansertib arm
- Not reached
- Onvansertib + FOLFIRI/bev arm
- Median PFS, combined SoC arms
- Approximately 11 months
- Combined standard-of-care arms
- Treatment duration
- At least 21 months
- Patients remaining in the 30 mg onvansertib + FOLFIRI/bev arm
- Longest treatment duration
- Over 29 months
- 30 mg onvansertib + FOLFIRI/bev arm
- Expected Phase 3 initiation
- Q1 2027
- Subject to securing additional financing
- Cash, cash equivalents, and short-term investments
- Approximately $33.8 million
- As of September 30, 2026
- Net cash used in operating activities
- Approximately $33.9 million
- Nine months ended September 30, 2026
- Cash runway
- Through the end of Q3 2027
- Company projection based on current expectations
Previous Earnings Reports
-
Reported Phase 2 data and selected the regimen for the planned first-line mCRC Phase 3 trial.
-
Reported 30 mg arm ORR and PFS results from the first-line mCRC Phase 2 trial.
-
Reported early ORR and PFS separation for onvansertib in the first-line mCRC Phase 2 trial.
-
Completed enrollment in the randomized Phase 2 trial evaluating onvansertib in first-line mCRC.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
progression-free survival medical
objective response rate medical
companion diagnostics medical
registered direct offering financial
orphan drug designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms
All patients remaining in the 30 mg onvansertib + FOLFIRI/bev arm have now exceeded 21 months on treatment
Company preparing for registrational Phase 3 trial in first-line RAS-mutated mCRC, with potential start in Q1 2027
SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.
“We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Building on the strength of these data, we are actively preparing for our upcoming registrational trial. There are currently no treatment options specifically approved for patients with pan-RAS-mutated mCRC in the first-line setting and we believe onvansertib has the potential to become an important new treatment for these patients.”
Clinical Highlights
Randomized Phase 2 Trial in First-Line RAS-Mutated Metastatic Colorectal Cancer (“mCRC”) Ongoing
Cardiff’s randomized Phase 2 trial evaluating onvansertib in combination with FOLFIRI/ bevacizumab (“bev”) or FOLFOX/bev as first-line therapy in patients with RAS-mutated mCRC remains ongoing. Median progression-free survival (“PFS”) has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm, the Company’s proposed Phase 3 regimen.
As of September 28, 2026, 6 patients remain on the FOLFIRI/bev regimen, with 5 patients in the onvansertib (20 or 30 mg) + FOLFIRI/bev arms and 1 patient on standard-of-care (“SoC”) FOLFIRI/bev. Patients who remain in the 30 mg onvansertib + FOLFIRI/bev arm have been on treatment for at least 21 months, with the longest duration of treatment being over 29 months. For comparison, the median PFS in the combined SoC arms has been reached at approximately 11 months, consistent with what has been historically reported.
Preparing for the Registrational Phase 3 Trial in First-Line RAS-Mutated mCRC
Cardiff expects to initiate the Phase 3 trial in the first quarter of 2027, subject to securing additional financing. In preparation, the Company is establishing key vendor relationships for trial execution and clinical supply materials, as well as finalizing the companion diagnostics for RAS mutational status. The trial is designed to support potential accelerated approval based on objective response rate and full approval based on PFS.
Corporate Updates
- In July, Cardiff completed a
$10 million registered direct offering of common stock and warrants to support working capital and general corporate purposes. The full press release is available here. - In September, Cardiff and its licensor, Nerviano Medical Sciences S.r.l. (“NMS”), resolved all outstanding disputes regarding global rights to onvansertib and amended their 2017 exclusive license agreement. The full press release is available here.
- In October, Cardiff appointed Leila Alland, MD, as interim Chief Medical Officer. Dr. Alland is a seasoned oncology executive who has served as Chief Medical Officer at several clinical-stage biotechnology companies and previously held leadership positions at AstraZeneca, Bristol Myers Squibb, Novartis and Schering-Plough, where she contributed to the development and approval of multiple oncology therapies. The full press release is available here.
- In October, U.S. Food and Drug Administration (“FDA”) granted Orphan Drug Designation (“ODD”) to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (“CMML”).
- In November, FDA granted ODD to onvansertib for the treatment of patients with small cell lung cancer.
Upcoming Events
- Cardiff management will present at the UBS Global Biopharma Conference and participate in one-on-one investor meetings on November 16–17, 2026. Dr. Mohindru’s presentation is scheduled for November 16 at 2:40 p.m. GMT. A live webcast and replay will be available in the “Events” section of the Cardiff Oncology website.
- Updated data from an investigator-sponsored clinical trial in CMML will be presented at the American Society of Hematology (“ASH”) Annual Meeting on December 13, 2026.
Third Quarter 2026 Financial Results
Liquidity, cash burn, and cash runway
As of September 30, 2026, Cardiff Oncology had approximately
Operating results
Total operating expenses were approximately
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company targeting RAS-mutated cancers via innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.
For more information, please visit https://www.cardiffoncology.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially.
There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, uncertainties associated with clinical development and regulatory approvals; the possibility that results from earlier clinical studies may not be predictive of future results; risks related to the timing, initiation, conduct and completion of clinical trials; the Company's need for additional financing; dependence on key personnel and third parties; competition; intellectual property risks; and other factors described in Cardiff Oncology's filings with the Securities and Exchange Commission. There can be no assurance that onvansertib will receive regulatory approval for any indication or prove commercially successful.
Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.
Investor Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
| Cardiff Oncology, Inc. Condensed Statements of Operations (in thousands, except for per share amounts) (unaudited) | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||
| Royalty revenues | $ | 171 | $ | 120 | $ | 316 | $ | 350 | ||||||||||
| Costs and expenses: | ||||||||||||||||||
| Research and development | 5,029 | 8,197 | 17,709 | 30,254 | ||||||||||||||
| Selling, general and administrative | 4,361 | 3,897 | 14,291 | 11,229 | ||||||||||||||
| Total operating expenses | 9,390 | 12,094 | 32,000 | 41,483 | ||||||||||||||
| Loss from operations | (9,219) | (11,974) | (31,684) | (41,133) | ||||||||||||||
| Other income (expense), net: | ||||||||||||||||||
| Interest income | 363 | 716 | 1,251 | 2,492 | ||||||||||||||
| Other income (expense), net | (1) | — | (1) | 6 | ||||||||||||||
| Total other income (expense), net | 362 | 716 | 1,250 | 2,498 | ||||||||||||||
| Net loss | (8,857) | (11,258) | (30,434) | (38,635) | ||||||||||||||
| Preferred stock dividend | (6) | (6) | (18) | (18) | ||||||||||||||
| Net loss attributable to common stockholders | $ | (8,863) | $ | (11,264) | $ | (30,452) | $ | (38,653) | ||||||||||
| Net loss per common share — basic and diluted | $ | (0.12) | $ | (0.17) | $ | (0.43) | $ | (0.58) | ||||||||||
| Weighted-average shares outstanding — basic and diluted | 76,178 | 66,879 | 71,004 | 66,644 | ||||||||||||||
| Cardiff Oncology, Inc. Condensed Balance Sheets (in thousands) (unaudited) | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 12,060 | $ | 17,470 | ||||
| Short-term investments | 21,730 | 40,834 | ||||||
| Accounts receivable and unbilled receivable | 90 | 182 | ||||||
| Prepaid expenses and other current assets | 1,146 | 1,642 | ||||||
| Total current assets | 35,026 | 60,128 | ||||||
| Property and equipment, net | 364 | 578 | ||||||
| Operating lease right-of-use assets | 225 | 629 | ||||||
| Other assets | 799 | 549 | ||||||
| Total Assets | $ | 36,414 | $ | 61,884 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 693 | $ | 8,087 | ||||
| Accrued liabilities | 7,358 | 7,577 | ||||||
| Operating lease liabilities | 265 | 730 | ||||||
| Total current liabilities | 8,316 | 16,394 | ||||||
| Operating lease liabilities, net of current portion | — | 102 | ||||||
| Total Liabilities | 8,316 | 16,496 | ||||||
| Stockholders’ equity | 28,098 | 45,388 | ||||||
| Total liabilities and stockholders’ equity | $ | 36,414 | $ | 61,884 | ||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Cardiff Oncology's Phase 2 colorectal cancer trial show?
Median progression-free survival was not reached in the 30 mg onvansertib plus FOLFIRI/bevacizumab arm, compared with approximately 11 months in the combined standard-of-care arms. Patients remaining in that onvansertib arm had been treated for at least 21 months, with the longest treatment duration exceeding 29 months.
When does Cardiff Oncology expect to start its Phase 3 trial?
Cardiff expects to initiate its first-line RAS-mutated metastatic colorectal cancer Phase 3 trial in the first quarter of 2027, subject to securing additional financing. The trial is designed to support potential accelerated approval based on objective response rate, which measures tumor responses, and full approval based on progression-free survival.
Why did Cardiff Oncology's research and development expenses decline?
The nine-month decline reflected completed clinical trials, fewer patients on treatment in the Phase 2 colorectal cancer trial, reduced preclinical activities and completed chemistry, manufacturing and controls activities. Research and development expense was $17.709 million for the nine months ended September 30, 2026, versus $30.254 million a year earlier.
When will Cardiff Oncology present updated chronic myelomonocytic leukemia trial data?
Updated data from an investigator-sponsored trial in chronic myelomonocytic leukemia will be presented at the American Society of Hematology Annual Meeting on December 13, 2026.